This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary The ADC sector has entered a phase of rapid commercial maturation and intense patent competition. A handful of Western incumbents — Daiichi Sankyo/AstraZeneca, Pfizer/Seagen, Roche/Genentech, Gilead, and AbbVie/ImmunoGen — dominate the approved product landscape with 10+ marketed ADCs between them. China has emerged as the world’s most prolific ADC patent-filing geography, led by Jiangsu Hengrui (31 pipeline ADCs, 1 approved in 2025), RemeGen (1 approved, 10+ pipeline), and Innovent Biologics. The…
Author: Eureka LS
This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. I. Executive Summary PARP (Poly ADP-Ribose Polymerase) inhibitors represent one of oncology’s most validated and commercially successful target classes. From the first FDA approval of olaparib in December 2014 to the most recent approval of senaparib in China (January 2025), the class now counts 7 approved products across ovarian, breast, prostate, and endometrial cancers. The patent landscape comprises 4,524 indexed patents with filings peaking at 542 in 2022 and remaining elevated at 441–514…
This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Abstract NLRP3 (NLR Family Pyrin Domain Containing 3 / Cryopyrin) is the sensor component of the NLRP3 inflammasome — a multi-protein complex that drives caspase-1 activation, IL-1β/IL-18 maturation, and pyroptosis in response to cellular stress signals. Dysregulated NLRP3 activation underlies a broad spectrum of inflammatory, metabolic, cardiovascular, and neurodegenerative diseases, making it one of the most compelling drug targets of the decade. As of May 2026, the space has 286 registered drugs (249…
This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary Tofacitinib Citrate (Xeljanz, Pfizer) was the first oral JAK inhibitor approved globally (November 2012) and remains a major asset in inflammatory disease. However, it now faces a fundamentally transformed competitive arena: the JAK inhibitor class has expanded to 15+ approved drugs across JAK1/2/3 targets, with newer, more selective agents — especially AbbVie’s upadacitinib — actively capturing share across tofacitinib’s core indications. A landmark FDA black-box warning (cardiovascular risk, malignancy, thrombosis) has…
This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary SOS1 (Son of Sevenless Homologue 1), the guanine nucleotide exchange factor (GEF) that catalyzes RAS activation, is a validated oncology target rationally paired with direct KRAS inhibitors to overcome adaptive resistance. As of mid-2026, the global arena contains one active Western clinical-stage program (Bayer’s BAY-3498264, Phase 1) alongside four active Chinese clinical-stage programs (ZG2001, HY-0006, SYH-2038, HW071021), representing a pronounced geographic asymmetry. Two early Western leaders — Boehringer Ingelheim (BI-1701963) and…
This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary SLE is a chronic, relapsing multisystem autoimmune disease with a prevalence of ~72.8/100,000 in the US, disproportionately affecting reproductive-age females and individuals of Black, Hispanic, and Asian ancestry. The competitive landscape has undergone a structural transformation since 2021: after decades with only hydroxychloroquine and corticosteroids as the standard backbone, the field now has ≥10 newly approved drugs since 2021 (including the first CAR-T therapies approved in China) and 34 Phase 3…
This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Abstract PRMT5 (Protein Arginine Methyltransferase 5) has emerged as one of the most compelling synthetic-lethality targets in oncology, driven by the discovery that MTAP-deleted tumors — which accumulate the metabolite MTA — are selectively hypersensitive to PRMT5 inhibition. The field has bifurcated into classical (non-selective) PRMT5 inhibitors and MTA-cooperative PRMT5 inhibitors that exploit the MTAP-deletion context for a wider therapeutic window. As of May 2026, 131 drugs have been identified against PRMT5/MTA-PRMT5, with…
This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary Pfizer occupies a Tier 1 global leadership position in biopharmaceuticals, with scale, therapeutic breadth, and manufacturing capabilities that few peers can match. However, the company is navigating a challenging post-COVID transition: COVID-related revenues (Comirnaty + Paxlovid) have declined significantly from peak levels, and the 2023 Seagen acquisition ($43B) brought a world-class ADC oncology engine alongside heavy integration costs and asset impairments. The 2025 strategic reset — consolidating ORD and PRD into…
This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary The global acetaminophen market is a multi-billion-dollar, structurally mature arena valued at approximately USD 14.1 billion by 2030 (total finished-product and API combined), with the API segment alone at ~USD 1.27 billion in 2024 growing at ~2.7% CAGR. The arena splits cleanly into three competitive layers: (1) OTC consumer-health brands (Kenvue/Tylenol, Haleon/Panadol) competing on brand equity and formulation differentiation; (2) API manufacturers (Granules India, Mallinckrodt, Hebei Jiheng, Anhui BBCA, CSPC) competing…
This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary Esophageal carcinoma encompasses two major histological subtypes: esophageal squamous cell carcinoma (ESCC), predominant in Asia (particularly China), and esophageal adenocarcinoma (EAC), more prevalent in Western markets. The global pipeline contains 261 drugs in active development (461 including roll-up indications). The competitive arena has undergone a step-change transformation since 2019: checkpoint inhibitors are now the standard first-line backbone across both histologies, and the field is now crowded with 20+ approved immunotherapy agents…